Innate Pharma (IPHA) Competitors $1.98 -0.03 (-1.58%) As of 10:38 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPHA vs. CRON, VIR, ABCL, IOVA, KALV, IMTX, DAWN, SION, ORIC, and XERSShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Cronos Group (CRON), Vir Biotechnology (VIR), AbCellera Biologics (ABCL), Iovance Biotherapeutics (IOVA), KalVista Pharmaceuticals (KALV), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), Sionna Therapeutics (SION), ORIC Pharmaceuticals (ORIC), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Its Competitors Cronos Group Vir Biotechnology AbCellera Biologics Iovance Biotherapeutics KalVista Pharmaceuticals Immatics Day One Biopharmaceuticals Sionna Therapeutics ORIC Pharmaceuticals Xeris Biopharma Innate Pharma (NASDAQ:IPHA) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Do analysts recommend IPHA or CRON? Innate Pharma presently has a consensus price target of $11.00, indicating a potential upside of 455.70%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Innate Pharma is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IPHA or CRON more profitable? Innate Pharma has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Innate Pharma's return on equity of 0.00% beat Cronos Group's return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Cronos Group -42.65%-2.56%-2.47% Does the MarketBeat Community prefer IPHA or CRON? Cronos Group received 416 more outperform votes than Innate Pharma when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 60.00% of users gave Innate Pharma an outperform vote. CompanyUnderperformOutperformInnate PharmaOutperform Votes4860.00% Underperform Votes3240.00% Cronos GroupOutperform Votes46461.13% Underperform Votes29538.87% Do institutionals and insiders hold more shares of IPHA or CRON? 0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 7.3% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, IPHA or CRON? Innate Pharma has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Which has preferable earnings & valuation, IPHA or CRON? Innate Pharma has higher earnings, but lower revenue than Cronos Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$12.62M14.46-$8.19MN/AN/ACronos Group$124.59M6.11-$73.96M$0.1315.19 Does the media prefer IPHA or CRON? In the previous week, Cronos Group had 3 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Cronos Group and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.87 beat Cronos Group's score of 1.04 indicating that Innate Pharma is being referred to more favorably in the media. Company Overall Sentiment Innate Pharma Very Positive Cronos Group Positive SummaryInnate Pharma beats Cronos Group on 11 of the 17 factors compared between the two stocks. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$182.46M$3.10B$5.60B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E RatioN/A33.2727.2320.02Price / Sales14.46468.94417.65154.33Price / CashN/A168.6838.2534.64Price / Book2.873.447.124.70Net Income-$8.19M-$72.35M$3.23B$247.97M7 Day Performance-7.93%7.57%2.74%2.64%1 Month Performance-12.99%18.09%8.94%6.39%1 Year Performance-19.53%-16.71%31.59%13.95% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma3.2977 of 5 stars$1.98-1.6%$11.00+455.7%-22.5%$182.46M$12.62M0.00220Positive NewsGap DownCRONCronos Group1.9208 of 5 stars$1.96-1.0%N/A-21.0%$755.94M$124.59M-15.08450Positive NewsVIRVir Biotechnology3.0685 of 5 stars$5.43-0.4%$32.86+505.1%-50.6%$750.63M$14.30M-1.39580Positive NewsABCLAbCellera Biologics2.6464 of 5 stars$2.51+2.9%$8.33+232.0%-5.8%$749.04M$23.11M-4.11500Options VolumeIOVAIovance Biotherapeutics4.6554 of 5 stars$2.21+7.8%$13.30+501.8%-74.0%$737.99M$212.68M-1.48500Trending NewsHigh Trading VolumeKALVKalVista Pharmaceuticals4.0646 of 5 stars$14.76+2.8%$24.83+68.2%+10.5%$733.81MN/A-4.05100Positive NewsInsider TradeAnalyst RevisionIMTXImmatics2.6716 of 5 stars$6.00+0.5%$14.67+144.4%-55.1%$729.30M$144.15M-9.09260Positive NewsAnalyst RevisionDAWNDay One Biopharmaceuticals1.6174 of 5 stars$7.08-1.5%$30.57+331.8%-46.2%$728.79M$161.92M-6.8760SIONSionna TherapeuticsN/A$16.46-4.4%$38.50+133.9%N/A$726.28MN/A0.0035ORICORIC Pharmaceuticals3.9072 of 5 stars$9.86+5.8%$19.17+94.4%+17.2%$700.93MN/A-5.4280News CoverageAnalyst RevisionXERSXeris Biopharma3.9276 of 5 stars$4.48-2.2%$6.25+39.5%+90.4%$700.61M$222.55M-9.96290Analyst Revision Related Companies and Tools Related Companies CRON Alternatives VIR Alternatives ABCL Alternatives IOVA Alternatives KALV Alternatives IMTX Alternatives DAWN Alternatives SION Alternatives ORIC Alternatives XERS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPHA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IPHA Stock Free IPHA Stock Alerts